Therapeutic methods for the treatment of prostate cancer are described. The methods include a gene therapy method for prostate cancer using the BRCA family of genes, including the BRCA1 and BRCA2 genes. The BRCA family of gene products inhibit the growth and tumorigenesis of prostate cancer cells. Therapeutic methods using the BRCA family of gene products are also described.
In accordance with the present invention, there are provided amphiphilic polyamine compounds and derivatives thereof having the property of promoting transfection of polynucleotides and polypeptides into cells, and formulations comprising said compounds.
The invention relates to cell proliferation, cell differentiation, male infertility, male fertility and to compositions and methods involved therein. Also methods of culturing spermatogonial stem cells with bone morphogenetic protein 8 are disclosed.
A novel method of treating human diseases using natural products found in roasted coffee. The use of natural products or derivatives thereof would permit the general public to improve their health without having to use prescription drugs.
The mutant SERTs we have developed can provide for a platform to screen for novel modes/molecules interrupting SERT function. As SERT blockers are effective antidepressants, this strategy can lead to novel antidepressant medications. It may also be useful in development of animal models to test antidepressant action in vivo.
The only MMP-7-null mouse that has been generated. Used to determine biological function of MMP-7. Mice have been used in more than 10 publications at this point, and will be distributed by a commercial vendor in the near future.
We produced a plasmid containing the Fc portion of mouse IgGl (Fc) coupled to human fibroblast growth factor 1 (FGF-1). The plasmid was transformed into E. coli to express the fusion protein. The fusion protein was purified on a heparin sepharose column which has high affinity for the FGF portion of the fusion protein. The purpose of making this protein was to be able to identify cells that express receptors for FGF using flow cytometry.There are multiple fluorochrome labeled antibodies to mouse IgGl. When the fusion protein is bound to FGF receptors on cells, the Fc portion is on the surface of the cells and can be detected by fluorochrome labeled antibodies to mouse IgGl. Therefore, cells that express FGF receptors and bind the fusion protein can be detected by flow cytometry or immunofluorescence.
The mutation allows for the first genetic test to be conducted for one form of chronic fatigue or mitral valve prolapse which we describe as orthostatic intolerance or postural tachycardia syndrome (POTS). The technology allows for the development of this test and the development of other tests in the same gene at other loci that may contribute to similar illnesses. The awareness of a phenotype associated with the mutation in the antidepressant-sensitive NET allows for evaluation of the role of the NET gene in mental illness and thus the development of genetic tests for increased susceptibility to mental and autonomic illnesses. This is the first neurotransmitter transporter gene defect that has been shown to be linked to a disorder. The precedent act opens the door for screening for other genetic mutations in genetically related transporters such as the serotonin transporter or dopamine transporter. These latter transporters have been implicated in depression anxiety, pscyhostimulant abuse (cocaine/amphetamine) and attention-deficit disorder. Our work allows for genetic inspection of transporter genes associated with these disorders. Our work may also allow for an examination of whether circulating antibodies against the NE transporter are contributory to OI or other chronic fatigue disorders.
In 2009 over 70,000 American were diagnosed with urinary bladder cancer, and in that same year over 14,000 Americans died of bladder cancer. Low funding for bladder cancer helps explain the slow progress in both the identification of biomarkers and the development of new treatments for metastatic bladder cancer. Nonetheless, novel diagnostic biomarkers are needed to aid in the early identification of patients with bladder cancer, and also to determine which patients are likely to progress. Vanderbilt researchers have identified such a biomarker whose expression is reduced and lost during progression of bladder cancer.
CORES™ is a highly configurable, enterprise-wide software solution for research institutions. CORES™ provides full central oversight while also allowing for flexible but consistent decentralized billing and usage functionality for core facilities. This software allows core managers and customers to enter orders using a variety of methods. The software also allows customers in product cores to scan their items at a self-service checkout terminal that provides full real-time inventory management. Orders are accumulated into electronic invoices and e-mailed to customers each month. An electronic upload file containing order information is also created for the finance department. Vanderbilt has approximately 90 internal cores using this software. In addition, the software is used by several other institutions to whom the software has been licensed.
The Patient Safety Screening Tool (PSST) for Sepsis solution is a tool to assist with the early detection of Sepsis and management of the administration of bundle packages as defined by the Institute for Healthcare Improvement (IHI). This web based application relies on integration with bedside medical equipment (BME) data as well as Lab and Registration data so that clinical workflow items can be automated in the fight against Sepsis.